Luso del placebo in studi su patologie con dolore Pierangelo Geppetti Farmacologia Clinica, Università di Firenze Centro Cefalee, AOU S. Anna, Ferrara.
ASCOs eighth annual Clinical Cancer Advances report identifies this years most significant clinical cancer advances Highlights 17 most important advances,
TIC TACS or TREATMENT Anti-depressants vs Placebo Joan R. Shepherd, FNP.
San Francisco High Risk EM titbits May 2012 Dr Cynthia Lim.
Tony Traboulsee, MD (Neurology) University of British Columbia CMSC June 5th, 2004 Toronto, Ontario Defining suboptimal response to MS treatment: MRI outcome.
TOK Across the Curriculum. Knower(s) Groups 1 and 2 Can translations ever be trusted to carry the original intent?
Mortality Outcome Predictors G. Van den Berghe Frontiers in Neuroendocrinology 23 (2002) : 370-391.
Back to the Future: Applying New Evidence in Menopause Management Michael Policar, MD, MPH.
Improving FDAs approach to new drug approval and post-marketing surveillance Jerry Avorn, M.D. Professor of Medicine, Harvard Medical School Chief, Division.
Sustainable Medicine New Directions for Research David Servan-Schreiber, MD, Ph.D Clinical Professor of Psychiatry, University of Pittsburgh Lecturer,
FIL SPM Course 2010 Voxel-Based Morphometry & DARTEL By John Ashburner & Ged Ridgway.
(C)Stephen Senn1 Lost Opportunities for Design Theory in Drug Development Stephen Senn.